• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/16/21 1:15:57 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LTRN alert in real time by email
    SC 13G 1 tm216774d1_sc13g.htm SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    Amendment #

     

    LANTERN PHARMA Inc.
    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)

     

    51654W101
    (CUSIP Number)

     

    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    ¨ Rule 13d-1(c)

     

    x Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 51654W101
    (1)

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

    Arunkumar Asaithambi

    (2)

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    N/A

    (3)

    SEC Use Only

     

    (4)

    Citizenship or Place of Organization

     

    India

    Numbers of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    (5)

    Sole Voting Power

     

    470,460

    (6)

    Shared Voting Power

     

    0

    (7)

    Sole Dispositive Power

     

    470,460

    (8)

    Shared Dispositive Power

     

    0

    (9)

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    470,460

    (10)

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ¨

     

    Not applicable.

    (11)

    Percent of Class Represented by Amount in Row (9)

     

    4.5%

    (12)

    Type of Reporting Person (See Instructions)

     

    IN

     

    Page 2 of 5

     

     

    Item 1.

     

    (a)Name of Issuer

     

    Lantern Pharma Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

     

    1920 McKinney Ave.

    7th Floor
    Dallas, TX 75201

     

    Item 2.

     

    (a)Name of Person Filing

     

    Arunkumar Asaithambi

     

    (b)Address of Principal Business Office or, if none, Residence

     

    3 Pleasant Lane, Oyster Bay, NY 11771

     

    (c)Citizenship

     

    India

     

    (d)Title of Class of Securities

     

    Lantern Pharma Inc. common stock $0.0001 par value per share

     

    (e)CUSIP Number

     

    51654W101

     

    Item 3.

     

    Not Applicable.

     

    Item 4.

     

    The stock ownership information below is presented as of the date hereof, which consists of 426,960 shares of common stock held by the reporting person and 43,500 shares of common stock which may be acquired pursuant to an option arrangement. The percentage set forth below is based on 10,503,292 shares of Common Stock issued and outstanding as of January 20, 2021, as represented in the Company’s Prospectus filed with the Securities and Exchange Commission on January 15, 2021 (the “January Prospectus”), plus 43,500 shares issuable upon the exercise of outstanding options. As of December 31, 2020, the reporting person’s stock ownership consisted of 441,960 shares of common stock held by the reporting person and 43,500 shares of common stock which may be acquired pursuant to an option arrangement. The shares of common stock constituted 7.7% of the Company’s outstanding common stock based on 6,220,927 shares outstanding as of November 6, 2020 as reported in the January Prospectus, plus 43,500 shares issuable upon the exercise of outstanding options. As of the date hereof, the Company had completed the public offering contemplated by the January Prospectus, resulting in the percentage ownership set forth below.

     

    (a)Amount beneficially owned:

     

    470,460

     

    Page 3 of 5

     

     

    (b)Percent of class:

     

    4.5%

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote

     

    470,460

     

    (ii)Shared power to vote or to direct the vote

     

    0

     

    (iii)Sole power to dispose or to direct the disposition of

     

    470,460

     

    (iv)Shared power to dispose or to direct the disposition of

     

    0

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following: x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    Not applicable.

     

    Page 4 of 5

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 12, 2021 By: /s/ Arunkumar Asaithambi
        Name: Arunkumar Asaithambi

     

    Page 5 of 5

     

    Get the next $LTRN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LTRN

    DatePrice TargetRatingAnalyst
    3/11/2022$34.00 → $36.00Buy
    HC Wainwright & Co.
    11/2/2021$32.00 → $34.00Buy
    HC Wainwright & Co.
    10/7/2021$32.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $LTRN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials

      Independent research from Johns Hopkins validates Lantern's data used to secure the FDA Rare Pediatric Disease Designation for LP-184 in ATRT and supports planned pediatric clinical trial Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biopharmaceutical company leveraging advanced AI and machine learning to transform the cost, pace, and timeline of oncology drug development, today announced promising preclinical data for LP-184 in atypical teratoid rhabdoid tumors (ATRT), a rare and aggressive pediatric brain cancer. The results were presented by Dr. Eric Raabe of Johns Hopkins University School of Medicine at the Society for Neuro-Oncology's 8th Biennial Pediatric Neuro-Oncology Co

      5/29/25 8:30:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

      Completion of LP-184 Phase 1a clinical trial enrollment with 62-65 patients across a range of solid tumors expected by end of June 2025. Additional patient data readout from the HARMONIC™ Trial evaluating LP-300 in never-smokers with non-small cell lung cancer (NSCLC) anticipated in Q3 2025, including initial readout for patients from the Asian expansion cohort. Strengthened AI intellectual property portfolio with PCT publication of proprietary blood-brain barrier penetration prediction patent application; favorable PCT search report indicated no significant prior art. Expanded RADR® platform with innovative AI-powered module to improve the precision, cost and timeline of antibody

      5/15/25 8:45:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need

      Drug candidate LP-184 to be evaluated in combination with immune checkpoint inhibitors in biomarker-defined NSCLC patients with KEAP1 and/or STK11 mutations and low PD-L1 expression. The FDA has cleared the LP-184 investigational new drug (IND) application amendment for the treatment of a biomarker defined patient population of non-small cell lung cancer (NSCLC). The planned phase 1b/2 clinical trial plans to evaluate LP-184 in advanced NSCLC patients with KEAP1 and/or STK11 mutations and low expression of PD-L1 in combination with the immune checkpoint inhibitor therapies, nivolumab and ipilimumab. LP-184 is a synthetically lethal, novel small molecule advanced and developed with La

      5/12/25 9:00:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LTRN
    SEC Filings

    See more
    • SEC Form 144 filed by Lantern Pharma Inc.

      144 - Lantern Pharma Inc. (0001763950) (Subject)

      5/27/25 9:00:02 PM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Lantern Pharma Inc.

      144 - Lantern Pharma Inc. (0001763950) (Subject)

      5/27/25 8:58:37 PM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Lantern Pharma Inc.

      144 - Lantern Pharma Inc. (0001763950) (Subject)

      5/27/25 8:56:44 PM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LTRN
    Leadership Updates

    Live Leadership Updates

    See more
    • Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives

      DALLAS, Sept. 2, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced the addition of two senior industry executives to support the Company's clinical and manufacturing initiatives. Dr. Harry Kochat has been appointed Senior Director of Chemistry, Manufacturing and Controls (CMC) and Manufacturing Quality Affairs, where his responsibilities will include oversight of drug candidate manufacturing and quality control. Darlene Bunpian, MPH has been appointed Clinical Trial Project Manag

      9/2/21 8:59:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LTRN
    Financials

    Live finance-specific insights

    See more
    • Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

      Completion of LP-184 Phase 1a clinical trial enrollment with 62-65 patients across a range of solid tumors expected by end of June 2025. Additional patient data readout from the HARMONIC™ Trial evaluating LP-300 in never-smokers with non-small cell lung cancer (NSCLC) anticipated in Q3 2025, including initial readout for patients from the Asian expansion cohort. Strengthened AI intellectual property portfolio with PCT publication of proprietary blood-brain barrier penetration prediction patent application; favorable PCT search report indicated no significant prior art. Expanded RADR® platform with innovative AI-powered module to improve the precision, cost and timeline of antibody

      5/15/25 8:45:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

      Webcast to be held Thursday, May 15th, 9:00 a.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its first quarter 2025 operating and financial results webcast on Thursday, May 15, 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. Management intends to discuss the operating and financial results for the first quarter ended March 31, 2025 and provide guidance on upcoming milestones, clinical tria

      5/8/25 8:30:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

      HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025. LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential. Successfully dosed multiple pati

      3/27/25 4:01:00 PM ET
      $ACTU
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LTRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Lantern Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of Lantern Pharma with a rating of Buy and set a new price target of $36.00 from $34.00 previously

      3/11/22 6:29:59 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Lantern Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of Lantern Pharma with a rating of Buy and set a new price target of $34.00 from $32.00 previously

      11/2/21 6:34:51 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Lantern Pharma with a new price target

      HC Wainwright & Co. initiated coverage of Lantern Pharma with a rating of Buy and set a new price target of $32.00

      10/7/21 8:16:17 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LTRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Fletcher Aaron G.L. sold $168,419 worth of shares (56,237 units at $2.99) (SEC Form 4)

      4 - Lantern Pharma Inc. (0001763950) (Issuer)

      5/29/25 9:55:55 PM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Kreis Leslie W. sold $168,419 worth of shares (56,237 units at $2.99) (SEC Form 4)

      4 - Lantern Pharma Inc. (0001763950) (Issuer)

      5/29/25 9:53:24 PM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Keyser D Jeffrey exercised 3,832 in-the-money shares at a strike of $3.13 (SEC Form 4)

      4 - Lantern Pharma Inc. (0001763950) (Issuer)

      7/26/24 4:15:16 PM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LTRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Lantern Pharma Inc. (Amendment)

      SC 13D/A - Lantern Pharma Inc. (0001763950) (Subject)

      3/1/24 4:10:40 PM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Lantern Pharma Inc. (Amendment)

      SC 13G/A - Lantern Pharma Inc. (0001763950) (Subject)

      2/14/24 4:05:49 PM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Lantern Pharma Inc. (Amendment)

      SC 13D/A - Lantern Pharma Inc. (0001763950) (Subject)

      12/1/23 6:02:25 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care